Importantly, the findings in the present study that PSMA-EVs in serum were elevated in metastatic PC and CRPC patients and in metastatic RCC patients are consistent with the proposed use of PSMA-PET/CT. The gene discussed is FOLH1; the disease is renal cell carcinoma.